Trial · NCT04777201
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Main Study | STARTED | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 524 | |
| Main Study | STARTED | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 505 | |
| Main Study | STARTED | Substudy: Faricimab PTI | 0 | |
| Main Study | Safety-Evaluable Population | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 520 | |
| Main Study | Safety-Evaluable Population | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 505 | |
| Main Study | Safety-Evaluable Population | Substudy: Faricimab PTI | 0 | |
| Main Study | COMPLETED | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 453 | |
| Main Study | COMPLETED | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 415 | |
| Main Study | COMPLETED | Substudy: Faricimab PTI | 0 | |
| Main Study | NOT COMPLETED | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 71 | |
| Main Study | NOT COMPLETED | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 90 | |
| Main Study | NOT COMPLETED | Substudy: Faricimab PTI | 0 | |
| Substudy (Concurrent With Main Study) | STARTED | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 0 | |
| Substudy (Concurrent With Main Study) | STARTED | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 0 | |
| Substudy (Concurrent With Main Study) | STARTED | Substudy: Faricimab PTI | 117 | |
| Substudy (Concurrent With Main Study) | Modified Intent-to-Treat and Safety-Evaluable Population | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 0 | |
| Substudy (Concurrent With Main Study) | Modified Intent-to-Treat and Safety-Evaluable Population | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 0 | |
| Substudy (Concurrent With Main Study) | Modified Intent-to-Treat and Safety-Evaluable Population | Substudy: Faricimab PTI | 113 | |
| Substudy (Concurrent With Main Study) | Completed the Year 1 Substudy Visit | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | 0 | |
| Substudy (Concurrent With Main Study) | Completed the Year 1 Substudy Visit | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04777201/flow